TABLE 7.
Univariate and multivariate analysis for predictors of ICPI-induced polymyalgia rheumatica.
| Univariate analysis Or (95%CI) | p Value | Multivariate analysis Or (95%CI) | p Value | |
|---|---|---|---|---|
| Nivolumab | ||||
| Male | 2.034 (0.850–4.871) | 0.104 | 1.985 (0.828–4.759) | 0.124 |
| Older adults (≥70 years old) | 15.11 (4.642–49.149) | <0.001 | 15.02 (4.615–48.87) | <0.001 |
| Pembrolizumab | ||||
| Male | 0.216 (0.082–0.569) | 0.001 | 0.214 (0.081–0.564) | 0.002 |
| Older adults (≥70 years old) | 1.940 (0.683–5.516) | 0.205 | 1.980 (0.696–5.635) | 0.200 |
| Ipilimumab | ||||
| Male | 2.645 (0.578–12.10) | 0.193 | ||
| Older adults (≥70 years old) | N.A. | N.A. | ||
CI, Confidence interval, N.A., Not available.